These findings support the idea that some patients may have partial biologic resistance to incretin-based therapies, said Robert Glatter, MD, attending physician in the Department of Emergency Medicine at Lenox Hill Hospital in New York City, and Assistant Professor of Emergency Medicine at Zucker School of Medicine at Hofstra/ Northwell
Tools like journals, apps, or tracking devices can simplify the process of recording any side effects
Akkermansia+: 1 serving for daily microbiome support
Additionally, GLP-1 agonists suppress glucagon release , a hormone that raises blood sugar, and act on areas of the brain involved in appetite regulation
Incretin-based drugs are now being investigated and in some cases approved for a wide range of conditions, including cardiovascular disease, chronic kidney disease, sleep apnea, fatty liver disease (MASLD), neurodegenerative disorders, and even substance-use disorders